AbbVie Inc. (ABBV) Shares Sold by Botty Investors LLC
Botty Investors LLC reduced its stake in shares of AbbVie Inc. (NYSE:ABBV) by 12.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,890 shares of the company’s stock after selling 995 shares during the period. Botty Investors LLC’s holdings in AbbVie were worth $427,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in the stock. CapWealth Advisors LLC raised its position in AbbVie by 55.2% in the first quarter. CapWealth Advisors LLC now owns 1,797 shares of the company’s stock worth $103,000 after buying an additional 639 shares in the last quarter. Acropolis Investment Management LLC acquired a new position in AbbVie during the second quarter worth approximately $106,000. Hartford Financial Management Inc. raised its position in AbbVie by 100.0% in the second quarter. Hartford Financial Management Inc. now owns 1,958 shares of the company’s stock worth $115,000 after buying an additional 979 shares in the last quarter. Americafirst Capital Management LLC acquired a new position in AbbVie during the second quarter worth approximately $122,000. Finally, D. Scott Neal Inc. raised its position in AbbVie by 107.4% in the second quarter. D. Scott Neal Inc. now owns 1,999 shares of the company’s stock worth $124,000 after buying an additional 1,035 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.
AbbVie Inc. (NYSE:ABBV) traded up 0.16% on Friday, hitting $62.93. The company had a trading volume of 3,812,671 shares. The stock’s 50-day moving average price is $64.13 and its 200 day moving average price is $62.54. The company has a market capitalization of $102.48 billion, a P/E ratio of 18.15 and a beta of 1.50. AbbVie Inc. has a one year low of $45.45 and a one year high of $68.12.
AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, July 29th. The company reported $1.26 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.20 by $0.06. AbbVie had a return on equity of 161.46% and a net margin of 23.11%. The company had revenue of $6.43 billion for the quarter, compared to the consensus estimate of $6.20 billion. During the same quarter last year, the business posted $1.08 EPS. AbbVie’s revenue for the quarter was up 17.8% on a year-over-year basis. On average, analysts expect that AbbVie Inc. will post $4.81 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 15th. Investors of record on Friday, October 14th will be issued a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 3.62%. The ex-dividend date of this dividend is Wednesday, October 12th. AbbVie’s dividend payout ratio (DPR) is 65.71%.
ABBV has been the topic of a number of recent analyst reports. Vetr lowered AbbVie from a “strong-buy” rating to a “buy” rating and set a $67.78 price objective on the stock. in a research note on Thursday, June 23rd. Credit Suisse Group AG reissued a “buy” rating on shares of AbbVie in a research note on Sunday, July 10th. Jefferies Group reissued a “buy” rating on shares of AbbVie in a research note on Thursday, August 4th. Argus reissued a “buy” rating and issued a $85.00 price objective on shares of AbbVie in a research note on Monday, August 8th. Finally, Goldman Sachs Group Inc. reissued a “buy” rating and issued a $78.00 price objective on shares of AbbVie in a research note on Thursday, September 8th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. AbbVie currently has an average rating of “Buy” and a consensus price target of $70.68.
In other AbbVie news, insider Laura J. Schumacher sold 50,000 shares of AbbVie stock in a transaction dated Wednesday, September 7th. The stock was sold at an average price of $65.00, for a total transaction of $3,250,000.00. Following the transaction, the insider now directly owns 144,138 shares of the company’s stock, valued at approximately $9,368,970. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.11% of the company’s stock.
AbbVie Company Profile
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions.
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV).
Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.